<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02854579</url>
  </required_header>
  <id_info>
    <org_study_id>NavyGHB-P-01</org_study_id>
    <nct_id>NCT02854579</nct_id>
  </id_info>
  <brief_title>Neural Progenitor Cell and Paracrine Factors to Treat Hypoxic Ischemic Encephalopathy</brief_title>
  <official_title>Safety and Efficacy Study of Neural Progenitor Cell Transplantation and Paracrine Factors From Human Mesenchymal Stem Cells to Treat Newborn With Hypoxic-ischemic Encephalopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Navy General Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bethune International Peace Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Daping Hospital and the Research Institute of Surgery of the Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shangluo Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>252 Military Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Navy General Hospital, Beijing</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy and safety of allogenic neural
      progenitor cell and paracrine factors of human mesenchymal stem cells for patients with
      moderate/severe Hypoxic-Ischemic Encephalopathy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neonates diagnosed moderate/severe Hypoxic-Ischemic Encephalopathy after birth will receive
      routine therapy and be randomized to four arms for allogenic neural progenitor cells
      transplantation，paracrine factors of human mesenchymal stem cells intrathecal
      injection，combination of cell and factor or only routine therapy. Patients will be followed
      for neurodevelopmental outcome at 12 and 18 months in Pediatrics of Navy General Hospital.
      Magnetic Resonance Imaging, electroencephalogram, Bailey scores, Peabody development measure
      scale and Gross motor function measure assessment will be obtained in the following
      research.Results will be analyzed and described in study reports.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neonatal Behavioral Neurological Assessment</measure>
    <time_frame>14days after birth</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>number of adverse events</measure>
    <time_frame>7days after cell or factor injection</time_frame>
    <description>adverse events like fever、infection、seizures、hemorrhage coursed by interventions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neonatal Behavioral Neurological Assessment</measure>
    <time_frame>28days after birth</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bayley score</measure>
    <time_frame>12 months after birth</time_frame>
    <description>Gross motor function measure assessment for children diagnosed cerebral palsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bayley score</measure>
    <time_frame>18 months after birth</time_frame>
    <description>Gross motor function measure assessment for children diagnosed cerebral palsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peabody development measure scale</measure>
    <time_frame>12 months after birth</time_frame>
    <description>Gross motor function measure assessment for children diagnosed cerebral palsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peabody development measure scale</measure>
    <time_frame>18 months after birth</time_frame>
    <description>Gross motor function measure assessment for children diagnosed cerebral palsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of death</measure>
    <time_frame>1 years after birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related central nervous tumor as assessed by Magnetic Resonance Imaging or CT</measure>
    <time_frame>5 years after birth</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hypoxic-Ischemic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Neural progenitor cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three doses of Neural progenitor cell (4*10^6) intrathecally at 48-72h, 5d and 10d after birth.+routine therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paracrine factors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three doses of concentrated paracrine factors of human mesenchymal stem cell （0.5ml） intrathecally at 12h,24h,48h after birth.+routine therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Progenitor cell and paracrine factors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three doses of concentrated paracrine factors 0.5ml intrathecally at 12h,24h,48h after birth.And three doses of neural progenitor cell (4*10^6) intrathecally at 48-72h, 5d and 10d after birth.+routine therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>neonates only receive routine therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>neural progenitor cell</intervention_name>
    <description>Neural progenitor cells are derived from the same aborted human fetal forebrain.</description>
    <arm_group_label>Neural progenitor cell</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Paracrine factors</intervention_name>
    <description>The factors obtained from cultured human mesenchymal stem cells were concentrated 50 times</description>
    <arm_group_label>Paracrine factors</arm_group_label>
    <other_name>paracrine factor of human mesenchymal stem cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>progenitor cell and paracrine factors</intervention_name>
    <description>Neural progenitor cells will be received after paracrine factors therapy</description>
    <arm_group_label>Progenitor cell and paracrine factors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. gestational age ≥ 34weeks, body weight ≥ 2kg.

          2. 1 minute apgar score ≤3, and 5 minutes apgar score ≤5, OR umbilical arterial blood gas
             potential of hydrogen&lt;7.0, OR 30 minutes base excess≤-12 mmol/L, OR need for
             ventilation 5 minutes after birth.

          3. All infants must have signs of encephalopathy (such as convulsion, coma, dystonia,
             abnormal primitive reflex and irregular respiration) within 6 hours of age or
             continued abnormal EEG for more than 24h.

        Exclusion Criteria:

          1. Does not meet the inclusion criteria

          2. Suffer from other serious organic disease or congenital, hereditary metabolic diseases

          3. Intracranial active infection, or neuromuscular damage outside central nervous system

          4. potential of hydrogen / electrolyte disorders without improvement or stability

          5. Coagulation disorders associated with bleeding tendency

          6. Immune function is not perfect

          7. Patients or his guardian refuse consent.

          8. Patients or his guardian don't accept the follow-up schedule.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>14 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zuo Luan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Navy General Hosiptal</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zuo Luan, MD</last_name>
    <phone>18600317210</phone>
    <email>hjzyyerke@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Weipeng Liu, MD</last_name>
    <phone>13581797015</phone>
    <email>hjzyynicu@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Navy General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100048</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zuo Luan, MD</last_name>
      <email>hjzyyerke@163.com</email>
    </contact>
    <investigator>
      <last_name>Zuo Luan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Weipeng Liu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Navy General Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100048</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zuo Luan, MD</last_name>
      <phone>18600310270</phone>
      <email>hjzyyerke@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Weipeng Liu, MD</last_name>
      <phone>135581797015</phone>
      <email>hjzyynicu@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Zuo Luan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Weipeng Liu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Luan Z, Liu W, Qu S, Du K, He S, Wang Z, Yang Y, Wang C, Gong X. Effects of neural progenitor cell transplantation in children with severe cerebral palsy. Cell Transplant. 2012;21 Suppl 1:S91-8. doi: 10.3727/096368912X633806.</citation>
    <PMID>22507684</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2014</study_first_submitted>
  <study_first_submitted_qc>July 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2016</study_first_posted>
  <last_update_submitted>July 30, 2016</last_update_submitted>
  <last_update_submitted_qc>July 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Navy General Hospital, Beijing</investigator_affiliation>
    <investigator_full_name>Zuo Luan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Hypoxic-Ischemic Encephalopathy</keyword>
  <keyword>progenitor cell</keyword>
  <keyword>paracrine factor</keyword>
  <keyword>adipose mesenchymal stem cell</keyword>
  <keyword>neonate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Hypoxia-Ischemia, Brain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

